MECHANISMS OF STEROID ACTION AND RESISTANCE IN INFLAMMATION

Corticosteroid-insensitive asthma: molecular mechanisms

I M Adcock and S J Lane¹

Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK

¹Department of Respiratory Medicine, Adelaide and Meath Hospital, Tallaght, Dublin 24, Eire

(Requests for offprints should be addressed to I M Adcock; Email: ian.adcock@imperial.ac.uk)

Abstract

Corticosteroids are the most potent anti-inflammatory agents used to treat chronic inflammatory diseases such as bronchial asthma. However, there are a small number (<5%) of asthmatic patients who do not respond well, or at all, to corticosteroid therapy – the corticosteroid-resistant and corticosteroid-dependent patients. Although this phenomenon is relatively uncommon, it poses a difficult therapeutic problem because few alternative therapies are available and these patients account for >50% of the health care costs of asthma. If the mechanisms for corticosteroid insensitivity are understood they

may, in turn, provide insight into the key mechanism of corticosteroid action and allow a rational way to treat these individuals whose disease tends to be severe. Corticosteroid insensitivity is not limited to asthma and is a feature of other inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Thus, elucidation of the cause for the relative lack of corticosteroid response in this subgroup of asthmatic individuals may have important implications for other diseases.

Journal of Endocrinology (2003) **178**, 347–355

The molecular basis of inflammation in bronchial asthma

Inflammation is a central feature of many chronic lung diseases including bronchial asthma. The specific characteristics of the inflammatory response and the site of inflammation differ between these diseases, but all involve the recruitment and activation of inflammatory cells and changes in the structural cells of the lung. These diseases are characterised by an increased expression of many mediators involved in the inflammatory cascade, including cytokines, chemokines, growth factors, enzymes, receptors and adhesion molecules. Increased inflammatory gene transcription is regulated by pro-inflammatory transcription factors, such as nuclear factor- κ B (NF- κ B) and activator protein-1 (AP-1). For example, NF- κ B (Hart *et al.* 1998) and AP-1 (Demoly *et al.* 1992) are markedly activated in the epithelial cells of asthmatic patients and these transcription factors regulate many of the inflammatory genes that are abnormally expressed in asthma (Adcock & Caramori 2001).

Alterations in the structure of chromatin are critical to the regulation of gene expression (Urnov & Wolffe 2001). This chromatin structure is composed of nucleosomes which are particles consisting of ~146 bp DNA associated

with an octamer of two molecules each of core histone proteins (H2A, H2B, H3 and H4). In the resting cell, DNA is tightly compacted around these basic core histones, excluding the binding of the enzyme RNA polymerase II, which activates the formation of mRNA. This conformation of the chromatin structure is described as closed and is associated with suppression of gene expression. Acetylation of lysine residues on histones induces a relaxed DNA structure allowing gene transcription to occur. Transcriptional co-activators such as cAMP response element binding protein (CREB)-binding protein (CBP) have intrinsic histone acetyltransferase (HAT) activity, which is further activated by the binding of transcription factors. Changes in the phosphorylation status of HATs also affect their activity. Increased gene transcription is therefore associated with an increase in histone acetylation, whereas hypo-acetylation is correlated with reduced transcription or gene silencing (Urnov & Wolffe 2001).

NF- κ B and AP-1

NF- κ B is ubiquitously expressed and is able not only to control the induction of inflammatory genes in its own

right but it can enhance the activity of other cell- and signal-specific transcription factors (Barnes & Karin 1997). In addition, it is a major target for corticosteroids (Barnes & Karin 1997). NF- κ B is activated by all the stimuli thought to be important in asthma, including cytokines, such as tumour necrosis factor- α (TNF α) and interleukin (IL)-1 β , viruses and immune challenges (Barnes & Karin 1997, Baldwin 2001). Activation of cell surface receptors leads to phosphorylation of receptor-associated kinases. These kinases, in turn, phosphorylate specific intracellular kinases (inhibitor of NF- κ B kinase; IKK). Phosphorylation of IKKs results in phosphorylation of the NF- κ B cytoplasmic inhibitor (I- κ B α), which targets I- κ B α for proteosomal degradation. This releases NF- κ B from its inactive state, enabling nuclear translocation and binding to specific DNA response elements within the regulatory regions of responsive genes (Ghosh & Karin 2002).

AP-1 is a transcription factor complex that is formed by dimerisation of members of the *Fos* (c-Fos, Fra1 and Fra2) and *Jun* (c-Jun, Jun B and Jun D) proto-oncogene families and is defined by binding to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-response element (TRE) (Chang & Karin 2001, Shaulian & Karin 2002). In the resting cell, AP-1 is composed of dimers of the Jun family and has weak DNA binding and gene transactivating activities. When the cell is activated, the components of AP-1 change rapidly to Fos:Jun heterodimers of which c-Fos:c-Jun is the most abundant and much more active than the resting homodimer. Inducible AP-1 is formed after activation of specific mitogen-activated protein kinases (MAPKs) of which Jun N-terminal kinase (JNK) is a central component (Chang & Karin 2001). JNK increases AP-1's DNA binding and gene transactivating activity by increasing the production of c-Fos and by increasing the affinity of c-Jun for c-Fos. JNK also phosphorylates Ets-like kinase (Elk-1) which enhances c-Fos transcription (Chang & Karin 2001) by binding to the serum response element in its promoter. c-Jun transcriptional activation is mediated by a TRE that is bound by the transcriptional activator activating transcription factor 2 (ATF-2), either as a homodimer or as a heterodimer with c-Jun. In this way, c-Jun may autoregulate expression of its own gene. In addition, ATF-2 is phosphorylated by JNK (Chang & Karin 2001, Shaulian & Karin 2002) leading to increased c-Jun expression.

Glucocorticoid receptors

Corticosteroids exert their effects by binding to a cytoplasmic receptor (glucocorticoid receptor; GR) (Adcock & Caramori 2001). GRs are expressed in almost all cell types and are modular in structure. Thus, GR has several functional domains including a ligand-binding domain (LBD), a DNA-binding domain and two domains that are involved in transactivation of genes once binding to DNA

has occurred via association with other proteins (activation function; AF-1 and AF-2). The second activation domain (AF-2) lies within the LBD. The inactive GR is bound to a protein complex that includes two subunits of the heat shock protein hsp90, which thus act as molecular chaperones preventing the nuclear localisation of unoccupied GR. Once the ligand binds to GR, hsp90 dissociates, allowing the nuclear localisation of the activated GR-steroid complex and its binding as a dimer to specific DNA sequences (glucocorticoid response elements (GREs); GGTACAnnnTGTTCT) and interaction with co-activator complexes (Adcock & Caramori 2001).

Glucocorticoid-induced gene transcription

The number of genes per cell *directly* regulated by corticosteroids is estimated to be between 10 and 100, but many genes are indirectly regulated through an interaction with other transcription factors and co-activators. Corticosteroids may suppress inflammation by increasing the synthesis of anti-inflammatory proteins, such as annexin-1, IL-10, MAPK phosphatase-1 (MKP-1) and the inhibitor of NF- κ B, I- κ B α (Table 1). Glucocorticoid side-effects are manifold and their regulation, at the molecular level, involves both DNA-binding and non-DNA-binding events. It is likely that some side-effects, such as osteoporosis, glaucoma, growth retardation in children, wound healing and metabolic effects are mediated, at least in part, by DNA binding (Schacke *et al.* 2002a). GRs, as with other transcription factors, increase gene transcription through an action on chromatin remodelling and recruitment of RNA polymerase II to the site of local DNA unwinding (Karin 1998, Ito *et al.* 2000).

Switching off inflammatory genes

Cross-talk between GR and other transcription factors

The major anti-inflammatory effects of corticosteroids are thought to be due to repression of inflammatory and immune genes. The inhibitory effect of corticosteroids is due largely to protein-protein complex interactions between activated GR and transcription factors, such as NF- κ B and AP-1, which mediate the expression of these inflammatory genes (Karin 1998) (Fig. 1). The interplay between pro-inflammatory transcription factors and GR may reflect differing effects on histone acetylation/deacetylation (Ito *et al.* 2000).

The importance of cross-talk in GR actions is indicated by the construction of a GR dimerisation-deficient mutant mouse in which GR is unable to dimerise and therefore bind to DNA, thus separating the transactivation and transrepression activities of glucocorticoids (Reichardt *et al.* 1998). These animals, in contrast to GR knock-out animals, survive to adulthood. In these animals,

Table 1 Glucocorticoid-sensitive genes**Increased transcription**

Lipoprotein-1/annexin-1 (phospholipase A₂ inhibitor)
 β_2 -adrenoceptor
 Secretory leukocyte inhibitory protein (SLPI)
 Clara cell protein (CC10, phospholipase A₂ inhibitor)
 IL-1 receptor antagonist
 IL-1R2 (decoy receptor)
 I- κ B α (inhibitor of NF- κ B)
 MKP-1 (MAPK phosphatase)
 CD163 (scavenger receptor)

Decreased transcription

Cytokines
 (IL-1, 2, 3, 4, 5, 6, 9, 11, 12, 13, 16, 17, 18, TNF α , GM-CSF, SCF)
 Chemokines
 (IL-8, RANTES, MIP-1 α , MCP-1, MCP-3, MCP-4, eotaxin)
 Inducible nitric oxide synthase (iNOS)
 Inducible cyclo-oxygenase (COX-2)
 Endothelin-1
 NK₁ receptors, NK₂ receptors
 Adhesion molecules (ICAM-1, E-selectin)
 Cytoplasmic phospholipase A₂ (cPLA₂)

CD163, cluster differentiation 163; GM-CSF, granulocyte macrophage-cell stimulating factor; SCF, stem cell factor; RANTES, Regulated upon activation normal T-cell expressed and secreted; MIP1 α , macrophage inflammatory protein-1 α ; MCP, monocyte chemoattractant protein; NK, neurokinin; ICAM-1, intercellular adhesion molecule 1.

dexamethasone was able to inhibit AP-1- and NF- κ B-driven gene transcription but the ability to facilitate GRE-mediated effects such as cortisol suppression and thymocyte apoptosis was markedly attenuated. This also suggests that the development of glucocorticoids with a greater therapeutic window is possible.

In addition, corticosteroids may also play a role in repressing the action of MAPKs such as the extracellular regulated kinase (ERK) and JNK (Rider *et al.* 1996, Caelles *et al.* 1997, Swantek *et al.* 1997, Hirasawa *et al.* 1998). Thus, Caelles and colleagues have demonstrated that corticosteroids inhibit the phosphorylation and activation of JNK, resulting in a failure to phosphorylate c-Jun and Elk-1, reduced *c-fos* transcription and a marked reduction in AP-1 activity. More recently it has been shown that dexamethasone can rapidly induce the dual specificity MAPK inhibitor MKP-1 and thereby attenuate p38 MAPK activation (Kassel *et al.* 2001, Lasa *et al.* 2001, 2002). Rogatsky *et al.* (1998) have, in turn, shown reciprocal inhibition of rat GR reporter gene activity by JNKs by a direct phosphorylation of serine 246 whereas ERK can inhibit GR action by an indirect effect, possibly through phosphorylation of a co-factor.

Corticosteroid resistance

Although corticosteroids are highly effective in the control of asthma and other chronic inflammatory or immune

diseases, a small proportion of patients with asthma fail to respond even to high doses of oral corticosteroids (Leung & Bloom 2003). Resistance to the therapeutic effects of corticosteroids is also recognised in other inflammatory and immune diseases (Lamberts *et al.* 1996), including rheumatoid arthritis (Lane & Lee 1996) and inflammatory bowel disease (Hearing *et al.* 1999). Corticosteroid-resistant (CR) patients, although uncommon, present considerable management problems. It is likely that there is a spectrum of steroid responsiveness, with the rare resistance at one end, but a relative resistance is seen in patients who require high doses of inhaled and oral corticosteroids (corticosteroid-dependent asthma; CD) (Leung & Bloom 2003).

CR asthma has been defined as a failure of the forced expired volume in 1s to improve from a baseline value of $\leq 75\%$ predicted by $\geq 15\%$ after 14 days of treatment with 40 mg prednisolone orally, despite demonstrating $> 15\%$ reversibility to an inhaled β_2 agonist (Barnes *et al.* 1995). In addition to reduced changes in clinical symptoms following corticosteroid therapy, studies have shown that there is reduced suppression of IL-4 and IL-5 mRNA in bronchoalveolar lavage cells obtained from CR patients after 1 week of treatment with prednisolone, when compared with those of corticosteroid-sensitive (CS) asthmatic subjects (Leung *et al.* 1995). Bronchoalveolar lavage of a group of CR subjects revealed an increased number of cells expressing IL-2, IL-4 and IL-13 mRNA compared with CS asthmatics (Leung *et al.* 1995). This suggested

Figure 1 How glucocorticoids switch off inflammatory genes. Inflammatory genes are activated by inflammatory stimuli, such as IL-1 β or TNF α , acting through their receptors (CyR), resulting in activation of the transcription factors NF- κ B and AP-1. Upon activation, these are able to bind to specific recognition sites within the promoter regions of responsive genes (TF-RE) and stimulate transcription of inflammatory genes such as cytokines and other mediators following recruitment of the basal transcription complex (BTC). GRs, after activation by corticosteroids, translocate to the nucleus and bind to either a negative GR response element (nGRE) in the promoter of inflammatory genes inhibiting gene transcription or, more commonly, interact with and block the ability of AP-1 and NF- κ B from enhancing gene expression.

that the profile of cytokine expression may underlie the poor responsiveness to glucocorticoids in these patients.

Importantly for examining the molecular basis of corticosteroid insensitivity, CR asthma is also associated with impaired *in vitro* and *in vivo* responsiveness of peripheral blood mononuclear cells (PBMCs) to the suppressive effects of corticosteroids. Thus, in patients with CR and CD asthma there is a reduction in the inhibitory effect of corticosteroids on cytokine release in PBMCs (Dong *et al.* 1998, Kam *et al.* 1993, Leung & Bloom 2003 and references therein).

Molecular mechanisms of corticosteroid resistance

At a molecular level, resistance to the anti-inflammatory effects of glucocorticoids can be induced by several mechanisms. The reduction in corticosteroid responsiveness observed in cells from these subjects has been ascribed

to a reduced number of GR, altered affinity of the ligand for GR, reduced ability of the GR to bind to DNA or increased expression of inflammatory transcription factors, such as AP-1, that compete for DNA binding (Dong *et al.* 1998, Kam *et al.* 1993, Leung & Bloom 2003).

Defects in GR sequence and pharmacokinetics

Unlike familial corticosteroid resistance where there is a mutation in the LBD of GR and a subsequent resetting of the basal cortisol level, CR patients have normal cortisol levels and are not Addisonian (Malchoff *et al.* 1993). Using standard dexamethasone suppression tests, it has been shown that CR asthmatics do not have an altered secretory rate of endogenous cortisol or an altered sensitivity of the hypothalamic–pituitary–adrenal axis (Lane *et al.* 1996). Using chemical mutational analysis, no mutations in the GR of CR patients were observed (Lane *et al.* 1994). This was confirmed in a later study which used RT-PCR

(Adcock *et al.* 1995b). It is unlikely, therefore, that the defect in CR asthma lies in the structure of the GR.

Defects in ligand binding

We, and others, have previously demonstrated using whole cell binding assays no significant changes in monocyte and T-cell binding affinity (K_d) and receptor density of the GR in patients with CR asthma (Corrigan *et al.* 1991, Lane & Lee 1991). More recently, Sher *et al.* (1994) have described two patterns of ligand-binding abnormalities in CR asthmatics termed type 1 and 2. The more common type 1 defect was associated with reduced K_d of GR, normal receptor numbers and was specific to T cells. The less common type 2 defect was associated with reduced GR receptor density with a normal K_d and was seen in the total mononuclear cell population. These differences were detected only in the nucleus and not the cytoplasm, possibly reflecting an effect of a nuclear protein masking the GR ligand-binding site or in an altered conformation of the activated GR. This altered affinity of dexamethasone for GR may reflect either an intrinsic defect in the GR within these patients or may relate to changes in the receptor induced by the increased level of inflammation in more severe asthmatics. The reversal of the reduced binding affinity by incubation with normal media suggests that the latter is a more likely possibility (Irusen *et al.* 2002, Leung & Bloom 2003). The type 1 defect was reversible with serum deprivation and was mimicked by incubation of cells with high concentrations of IL-2 and IL-4 or by IL-13 alone (Irusen *et al.* 2002, Leung & Bloom 2003). In contrast, the type 2 defect was irreversible and was not IL-2 and IL-4 dependent (Sher *et al.* 1994).

Two explanations for the effect of IL-2/IL-4 or IL-13 alone on ligand-binding characteristics have been proposed. Leung & Bloom (2003) have associated these changes with an increased expression of the dominant negative isoform of GR, GR β , although others have been unable to detect enhanced GR β expression in PBMCs from these CR patients (Gagliardo *et al.* 2000, Irusen *et al.* 2002). In contrast, increased numbers of cells expressing GR β have been reported in skin biopsies from CR patients (Sousa *et al.* 2000). We have recently demonstrated that the effects of IL-2/IL-4 and IL-13 on GR-ligand binding and dexamethasone regulation of IL-10 release were blocked by the p38 MAPK inhibitor SB203580. Activation of p38 MAPK by IL-2/IL-4 resulted in serine phosphorylation of GR and reduced dexamethasone repression of lipopolysaccharide (LPS)-stimulated GM-CSF release. The ability of dexamethasone to modulate IL-10 release was also inhibited by IL-2/IL-4 co-treatment and restored by SB203580 (Irusen *et al.* 2002). These data showed that p38 MAPK inhibitors may have potential in reversing glucocorticoid insensitivity and

re-establishing the beneficial effects of glucocorticoids in patients with severe asthma.

It is unclear whether this is a direct or indirect effect of p38 MAPK or whether GR phosphorylation alters ligand binding affinity directly. This may result from either a change in GR conformation due to association of distinct co-factors, or partial blocking of the ligand-binding domain due to association of GR with nuclear transcriptional modulating proteins. Similar results have been seen following NO treatment of GR, whereby nitrosylation of GR at an hsp90 interaction site modified ligand binding (Galigniana *et al.* 1999). Serine 226 and the sequences immediately surrounding it are highly conserved, suggesting that its phosphorylation may alter or disrupt the protein-protein interactions regulating GR action.

GR nuclear translocation and GR/GRE binding

In one subgroup of CR and CD patients, nuclear localisation of GR in response to a high concentration (10^{-6} M) of dexamethasone was impaired (Matthews *et al.* 2000). The mechanism for this effect is unclear but may reflect changes in GR phosphorylation by MAPK and subsequent interaction with importin- α (Rogatsky *et al.* 1998, Savory *et al.* 1999, Irusen *et al.* 2002). This may also explain the earlier results we obtained using (Electrophoretic mobility shift assays (EMSAs) which showed that CR patients had a reduced level of GR:GRE binding compared with CS and non-asthmatic individuals following stimulation of PBMCs with dexamethasone (Adcock *et al.* 1995b). Scatchard analysis of GR:GRE binding showed no change in binding affinity but did show a reduced number of GR available for DNA binding in the CR patients. These results suggest that the ability of GR to bind to GRE is impaired in CR patients because of a reduced number of GR (Adcock *et al.* 1995b).

In a separate subgroup of CR patients, GR nuclear translocation was normal but dexamethasone could not correctly stimulate histone H4 acetylation (Matthews *et al.* 2000). This suggests that corticosteroids are not able to activate certain genes that are critical to the anti-inflammatory action of high doses of corticosteroids. The mechanism for this effect is unknown but may reflect the mutual inhibitory effects of excess JNK activation (Rogatsky *et al.* 1998) in these cells or a failure of GR to recruit specific co-activators.

Cross-talk with other transcription factors

We originally reported an increase in the basal levels of AP-1 DNA binding in the nuclei from CR patients although no differences in the sequences of *c-fos* and *c-jun* mRNA were detected. In addition, there was a reduced ability of GR to interact and repress AP-1 activity (Adcock *et al.* 1995a). It is also possible to see enhanced c-Fos expression in bronchial biopsies of CR patients (Fig. 2).

c-Fos

SR

SS

Figure 2 Enhanced expression of c-Fos in the bronchial airways of steroid (corticosteroid)-resistant (SR) asthmatics compared with steroid-sensitive subjects (SS). Increased intensity of dark brown immunohistological staining of c-Fos within the airway epithelium and infiltrating mononuclear cells in SR compared with SS subjects.

These results suggested that AP-1 is altered in CR patients and that increased levels of AP-1 may prevent GR function.

In a subsequent study using nuclear run-on, RT-PCR and Western blotting, we demonstrated a two- to fourfold greater increase in the *c-fos* transcription rate and mRNA and protein expression in PBMCs isolated from CR compared with CS asthmatics and normal subjects (Lane *et al.* 1998). When cells were stimulated with phorbol 12-myristate 13-acetate (PMA), the time- and concentration-dependent induction of c-Fos was greater in the CR group. Overexpression of c-Fos induced by stimulation of PBMCs derived from CS subjects with PMA for 6 h attenuated the ability of these cells to induce GR-GRE binding after 1 h of dexamethasone treatment. In these experiments, GR-GRE binding was reduced to levels similar to those seen in CR subjects. Incubation of PBMCs derived from CR subjects with dexamethasone

and with antisense oligonucleotides directed against *c-fos* increased GR-GRE binding to levels similar to those seen in CS individuals. These findings suggested that increased c-Fos under basal conditions is the predominant inhibitory activity on GR-DNA binding in CR asthma.

The results of these studies did not determine whether there is a specific abnormality in the activation of *c-fos* transcription in PBMCs derived from CR subjects or a more generalised activation of the components of AP-1 or their regulatory pathways which activate components of AP-1 through the serum response element (Shaulian & Karin 2002). Using the tuberculin response as a model of mononuclear cell inflammation, Sousa *et al.* (1999) subsequently showed a marked increase in the expression of activated phosphorylated c-Jun, enhanced expression of JNK, and greater up-regulation of c-Fos expression in the CR compared with the CS group. In this model, prednisolone suppressed memory T-cell, macrophage and

Figure 3 Potential mechanisms for corticosteroid insensitivity. Corticosteroids are lipophilic molecules that diffuse readily through cell membranes to interact with cytoplasmic receptors. Upon ligand binding, receptors (GR) are activated and translocate into the nucleus where they bind to specific DNA elements. Upon DNA binding, they induce acetylation of lysine residues 5 (K5⁺) and 16 (K16⁺) on histone H4 leading to modulation of gene transcription. Alternatively, GR can repress NF-κB- or AP-1-induced gene transcription. In some steroid-insensitive subjects (Group 1) GR is unable to translocate to the nucleus, possibly as a result of p38 MAPK-induced phosphorylation, and is thereby ineffective. In other steroid-insensitive subjects (Group 2), although GR can successfully translocate to the nucleus, it is unable to inhibit NF-κB and AP-1 and, in addition, has a reduced ability to induce histone acetylation on K5.

activated eosinophil infiltration into tuberculin-induced skin lesions of CS but not CR individuals. Prednisolone reduced the levels of both phosphorylated c-Jun and phosphorylated JNK in the CS but not the CR group without affecting total c-Jun and JNK expression.

The data to date suggest that increased levels of c-Fos and increased activation of c-Jun in patients with CR asthma account for the increased AP-1 activity seen *in vitro* and probably relates to increased activation of JNK in these subjects. JNK regulates the expression and activation of both major components of AP-1. Elevated JNK activity could be critical to the mechanisms of CR asthma and failure to inhibit JNK phosphorylation by glucocorticoids may be a major cause for the lack of response to glucocorticoids in CR asthma. In addition, JNK may, in turn, suppress GR function, resulting in a feed-forward loop of increasing inflammation and reduced corticosteroid responsiveness in these patients.

It is unclear whether increased *c-fos* transcription and JNK activation is a primary or secondary defect caused by

excessive production of a unique pattern of cytokines in asthmatic airways. At present there is no evidence for a genetic component leading to enhanced AP-1 activation in CR asthma. The increased numbers of bronchoalveolar lavage cells expressing IL-2 and IL-4 in the CR group may suggest a primary defect of cytokine regulation in these patients. T-helper 2 (TH₂) cytokines can enhance AP-1 expression (Wang *et al.* 1994) which, in turn, can switch on more TH₂ cytokines (de Groot *et al.* 1997), leading to a pro-inflammatory amplification loop. Irrespective of whether enhanced expression of AP-1 is primary or secondary, the net result is an excessive accumulation of this critical transcription factor.

Therapeutic implications

Inhaled glucocorticoids are now used as first-line therapy for the treatment of persistent asthma in adults and children in many countries, as they are the most effective

treatments for asthma currently available (Barnes 1995). However, at high doses systemic absorption of inhaled glucocorticoids may have deleterious effects, so there has been a search for safer glucocorticoids for inhalation and oral administration. This has led to a search for novel glucocorticoids that selectively *transrepress* without significant *transactivation*, thus reducing the potential risk of systemic side-effects.

Recently, a novel class of glucocorticoids has been described in which there is potent *transrepression* with relatively little *transactivation*. These 'dissociated' glucocorticoids, including RU24858 and RU40066 have anti-inflammatory effects *in vitro* (Vayssiere *et al.* 1997), although there is little separation of anti-inflammatory effects and systemic side-effects *in vivo* (Belvisi *et al.* 2001). This may reflect *in vivo* metabolism of the glucocorticoids. Several non-steroidal selective glucocorticoid receptor agonists (SEGRA) have recently been reported that show dissociated properties in human cells (Schacke *et al.* 2002b). Several of these dissociated glucocorticoids and SEGRA are now in clinical development and show good separation between *transrepression* and *transactivation* actions. This suggests that the development of glucocorticoids and SEGRA with a greater margin of safety is possible and may even lead to the development of oral compounds that do not have significant adverse effects. Alternatively, it may be possible to use MAPK inhibitors as steroid-sparing agents reducing the dose of corticosteroid needed to obtain effective therapy.

Conclusions

CR asthma is a syndrome of relative corticosteroid insensitivity, without a clear single pathophysiological cause, rather than a distinct disease with complete resistance to corticosteroids. Several mechanisms have been proposed to account for a failure to respond to corticosteroids (Fig. 3), including a reduced number of GR, altered affinity of the ligand for GR, reduced ability of the GR to bind to DNA or increased activation of transcription factors, such as AP-1, that compete for DNA binding. These events may not be completely exclusive, in that MAPK activation may lead to enhanced inflammation, reduced GR ligand and DNA binding and possibly enhanced GR β expression. The development of new dissociated corticosteroids may allow high enough doses of corticosteroids to be given to these patients to elicit therapeutic responses bypassing the problem of the deleterious side-effects normally seen in these patients. In addition, MAPK inhibitors may prove to be beneficial as corticosteroid-sparing agents.

References

- Adcock IM & Caramori G 2001 Cross-talk between pro-inflammatory transcription factors and glucocorticoids. *Immunology and Cell Biology* **79** 376–384.
- Adcock IM, Lane SJ, Brown CR, Lee TH & Barnes PJ 1995a Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. *Journal of Experimental Medicine* **182** 1951–1958.
- Adcock IM, Lane SJ, Brown CR, Peters MJ, Lee TH & Barnes PJ 1995b Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. *Journal of Immunology* **154** 3500–3505.
- Baldwin AS Jr 2001 Series introduction: the transcription factor NF-kappaB and human disease. *Journal of Clinical Investigation* **107** 3–6.
- Barnes PJ 1995 Inhaled glucocorticoids for asthma. *New England Journal of Medicine* **332** 868–875.
- Barnes PJ & Karin M 1997 Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *New England Journal of Medicine* **336** 1066–1071.
- Barnes PJ, Greening AP & Crompton GK 1995 Glucocorticoid resistance in asthma. *American Journal of Respiratory and Critical Care Medicine* **152** S125–S140.
- Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE & Foster ML 2001 Therapeutic benefit of a dissociated glucocorticoid and the relevance of *in vitro* separation of transrepression from transactivation activity. *Journal of Immunology* **166** 1975–1982.
- Caelles C, Gonzalez-Sancho JM & Munoz A 1997 Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. *Genes and Development* **11** 3351–3364.
- Chang L & Karin M 2001 Mammalian MAP kinase signalling cascades. *Nature* **410** 37–40.
- Corrigan CJ, Brown PH, Barnes NC, Szefer SJ, Tsai JJ, Frew AJ & Kay AB 1991 Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids *in vitro*. *American Reviews in Respiratory Disease* **144** 1016–1025.
- Demoly P, Basset SN, Chanez P, Campbell AM, Gauthier RC, Godard P, Michel FB & Bousquet J 1992 c-fos proto-oncogene expression in bronchial biopsies of asthmatics. *American Journal of Respiratory and Cell Molecular Biology* **7** 128–133.
- Dong Y, Poellinger L, Gustafsson JA & Okret S 1988 Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. *Molecular Endocrinology* **2** 1256–1264.
- Gagliardo R, Chanez P, Vignola AM, Bousquet J, Vachier I, Godard P, Bonsignore G, Demoly P & Mathieu M 2000 Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. *American Journal of Respiratory and Critical Care Medicine* **162** 7–13.
- Galigniana MD, Piwien-Pilipuk G & Assreuy J 1999 Inhibition of glucocorticoid receptor binding by nitric oxide. *Molecular Pharmacology* **55** 317–323.
- Ghosh S & Karin M 2002 Missing pieces in the NF-kappaB puzzle. *Cell* **109** (Suppl) S81–S96.
- De Groot RP, van Dijk TB, Caldenhoven E, Coffey PJ, Raaijmakers JA, Lammers JW & Koenderman L 1997 Activation of 12-O-tetradecanoylphorbol-13-acetate response element-and dyad symmetry element-dependent transcription by interleukin-5 is mediated by Jun N-terminal kinase/stress-activated protein kinase kinases. *Journal of Biological Chemistry* **272** 2319–2325.
- Hart LA, Krishnan VL, Adcock IM, Barnes PJ & Chung KF 1998 Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. *American Journal of Respiratory and Critical Care Medicine* **158** 1585–1592.
- Hearing SD, Norman M, Probert CS, Haslam N & Dayan CM 1999 Predicting therapeutic outcome in severe ulcerative colitis by measuring *in vitro* steroid sensitivity of proliferating peripheral blood lymphocytes. *Gut* **45** 382–388.
- Hirasawa N, Sato Y, Fujita Y, Mue S & Ohuchi K 1998 Inhibition by dexamethasone of antigen-induced c-Jun N-terminal kinase activation in rat basophilic leukemia cells. *Journal of Immunology* **161** 4939–4943.

- Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF & Adcock IM 2002 p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. *Journal of Allergy and Clinical Immunology* **109** 649–657.
- Ito K, Barnes PJ & Adcock IM 2000 Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1 beta-induced histone H4 acetylation on lysines 8 and 12. *Molecular Cell Biology* **20** 6891–6903.
- Kam JC, Szefer SJ, Surs W, Sher ER & Leung DY 1993 Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. *Journal of Immunology* **151** 3460–3466.
- Karin M 1998 New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? *Cell* **93** 487–490.
- Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M & Cato AC 2001 Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. *EMBO Journal* **20** 7108–7116.
- Lamberts SW, Huijzena AT, de LP, de JF & Koper JW 1996 Clinical aspects of glucocorticoid sensitivity. *Steroids* **61** 157–160.
- Lane SJ & Lee TH 1991 Glucocorticoid receptor characteristics in monocytes of patients with corticosteroid-resistant bronchial asthma. *American Review of Respiratory Disease* **143** 1020–1024.
- Lane SJ & Lee TH 1996 Corticosteroid resistance in other disease states and tissues. *American Journal of Respiratory and Critical Care Medicine* **154** S62–S65.
- Lane SJ, Arm JP, Staynov DZ & Lee TH 1994 Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma. *American Journal of Respiratory Cell and Molecular Biology* **11** 42–48.
- Lane SJ, Atkinson BA, Swaminathan R & Lee TH 1996 Hypothalamic–pituitary–adrenal axis in corticosteroid-resistant bronchial asthma. *American Journal of Respiratory and Critical Care Medicine* **153** 557–560.
- Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ & Lee TH 1998 Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. *Journal of Clinical Investigation* **102** 2156–2164.
- Lasa M, Brook M, Saklatvala J & Clark AR 2001 Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. *Molecular and Cellular Biology* **21** 771–780.
- Lasa M, Abraham SM, Boucheron C, Saklatvala J & Clark AR 2002 Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. *Molecular and Cellular Biology* **22** 7802–7811.
- Leung DY & Bloom JW 2003 Update on glucocorticoid action and resistance. *Journal of Allergy and Clinical Immunology* **111** 3–22.
- Leung DY, Martin RJ, Szefer SJ, Sher ER, Ying S, Kay AB & Hamid Q 1995 Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. *Journal of Experimental Medicine* **181** 33–40.
- Malchoff DM, Brufsky A, Reardon G, McDermott P, Javier EC, Bergh CH, Rowe D & Malchoff CD 1993 A mutation of the glucocorticoid receptor in primary cortisol resistance. *Journal of Clinical Investigation* **91** 1918–1925.
- Matthews JG, Ito K, Barnes PJ & Adcock IM 2000 Corticosteroid-resistant and corticosteroid-dependent asthma: two clinical phenotypes can be associated with the same *in vitro* defects in GR nuclear translocation and acetylation of histone H4. *American Journal of Respiratory and Critical Care Medicine* **161** A189.
- Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P & Schutz G 1998 DNA binding of the glucocorticoid receptor is not essential for survival. *Cell* **93** 531–541.
- Rider LG, Hirasawa N, Santini F & Beaven MA 1996 Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. *Journal of Immunology* **157** 2374–2380.
- Rogatsky I, Logan SK & Garabedian MJ 1998 Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. *PNAS* **95** 2050–2055.
- Savory JA, Hsu B, Laquian IR, Giffin W, Reich T, Hache RG & Lefebvre YA 1999 Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. *Molecular and Cellular Biology* **19** 1025–1037.
- Schacke H, Docke WD & Asadullah K 2002a Mechanisms involved in the side effects of glucocorticoids. *Pharmacology and Therapeutics* **96** 23–43.
- Schacke H, Hennekes H, Schottelius A, Jaroch S, Lehmann M, Schmees N, Rehwinkel H & Asadullah K 2002b SEGRAs: a novel class of anti-inflammatory compounds. *Ernst Schering Research Foundation Workshop* **40** 357–371.
- Shaulian E & Karin M 2002 AP-1 as a regulator of cell life and death. *Nature Cell Biology* **4** E131–E136.
- Sher ER, Leung DY, Surs W, Kam JC, Zieg G, Kamada AK & Szefer SJ 1994 Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. *Journal of Clinical Investigation* **93** 33–39.
- Sousa AR, Lane SJ, Soh C & Lee TH 1999 *In vivo* resistance to corticosteroids in bronchial asthma is associated with enhanced phosphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. *Journal of Allergy and Clinical Immunology* **104** 565–574.
- Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ & Lee TH 2000 Glucocorticoid resistance in asthma is associated with elevated *in vivo* expression of the glucocorticoid receptor beta-isoform. *Journal of Allergy and Clinical Immunology* **105** 943–950.
- Swantek JL, Cobb MH & Geppert TD 1997 Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. *Molecular and Cellular Biology* **17** 6274–6282.
- Urnov FD & Wolffe AP 2001 Chromatin remodeling and transcriptional activation: the cast (in order of appearance). *Oncogene* **20** 2991–3006.
- Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeu C, Gronemeyer H & Resche RM 1997 Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity *in vivo*. *Molecular Endocrinology* **11** 1245–1255.
- Wang CY, Bassuk AG, Boise LH, Thompson CB, Bravo R & Leiden JM 1994 Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors. *Molecular and Cellular Biology* **14** 1153–1159.

Received 6 March 2003

Accepted 23 June 2003